BioLargo, Inc.
BLGO
$0.2639
-$0.0002-0.08%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 62.84% | 246.75% | 27.20% | 108.29% | 78.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 62.84% | 246.75% | 27.20% | 108.29% | 78.13% |
| Cost of Revenue | 112.53% | 358.85% | 30.12% | 101.41% | 65.37% |
| Gross Profit | 20.00% | 160.93% | 24.09% | 116.37% | 90.82% |
| SG&A Expenses | -8.12% | 34.23% | 29.21% | 20.17% | 59.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -133.33% | 37.88% |
| Total Operating Expenses | 29.85% | 92.94% | 30.91% | 49.98% | 75.35% |
| Operating Income | 29.08% | 44.86% | -59.96% | 50.04% | -70.58% |
| Income Before Tax | 29.71% | 52.03% | -56.88% | 27.56% | -78.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.71% | 52.03% | -56.88% | 27.56% | -78.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 69.81% | 13.76% | 47.77% | -8.78% | -10.20% |
| Net Income | 55.25% | 66.79% | -65.99% | 33.06% | -138.10% |
| EBIT | 29.08% | 44.86% | -59.96% | 50.04% | -70.58% |
| EBITDA | 29.79% | 46.22% | -59.78% | 50.08% | -69.59% |
| EPS Basic | 57.14% | 68.09% | -55.56% | 35.90% | -121.05% |
| Normalized Basic EPS | 77.27% | 72.00% | -100.00% | 81.25% | -214.29% |
| EPS Diluted | 57.14% | 68.09% | -55.56% | 35.90% | -121.05% |
| Normalized Diluted EPS | 77.27% | 72.00% | -100.00% | 81.25% | -214.29% |
| Average Basic Shares Outstanding | 4.36% | 4.03% | 4.84% | 5.21% | 6.38% |
| Average Diluted Shares Outstanding | 4.36% | 4.03% | 4.84% | 5.21% | 6.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
